Welcome to the latest edition of the Frailomic Initiative Newsletter.

The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,

The first publication to come out of our UK Refractory Asthma

If you're managing a project, it's important to stay informed about work progress

World Asthma Day was first launched in 1998

The world's first human COVID challenge trial has been given the green light

The world's first human COVID challenge trial has been given the green light

There have been hundreds of thousands of deaths from COVID-19

We are pleased to bring you the latest edition of the MID-Frail newsletter

Many scientists believe that we have reached the end of the life-expectancy revolution

Welcome to the first issue of the MID‐Frail newsletter

All of our core studies have now completed their clinical phase

The world's first human COVID challenge trial has been given the green light

This essential reading provides readers with a round-up of news on the latest events

Clinical trials are not cheap to conduct, and with data integrity

In its recent white paper on severe asthma, The Severe Asthma Report 2017

Early in 2020, COVID-19 was spreading rapidly across the globe.

I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition

Academic Industry Meeting days (AIMdays)

Our publication on new therapies in the management of type 2 diabetes mellitus

However you may feel about the way political leaders have turned Brexit

Do you know what Good Laboratory Practice stands for? In nonclinical animal studies

Whether it’s a festival, concert or celebratory party, music unites people and pervades

As a jobbing scientist you rarely spend your whole career working on the same project.

Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.

If you have been involved in the pharmaceutical industry for any length

Read the latest newsletter from both our MID-Frail

Phenotype-specific omic expression patterns in people with frailty could provid

Every year, a huge amount of scientific data is released. It's out there, but how do you find it?

Our publication on sarcoidosis, a multisystem inflammatory disease

May 4 is often known as ‘Star Wars Day’. It is jokingly said

Read the latest newsletter here [1]. In this edition

The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations

Attend any research meeting, conference or clinical congress

Welcome to the latest issue of the Refractory Asthma Stratification Programme (RASP-UK)

Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.

Phase I is the lifeblood or new medicines. The UK’s Phase I representative body,

Welcome to the second issue of the Refractory Asthma Stratification

Experience at Niche has taught us that clinical study protocols are born in the white-hot fire

Metathesiophobia: from Preclinical to Clinical Development

When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.

With age comes wisdom, however the physical side of ageing

The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.

We've been sharing you our Insider's Insights with you for 2 years now.

You can now download our latest newsletter, detailing how 2014

The latest issue of Journal Frontiers in Pharmacology has just published

MID‐Frail News returns with this Special Issue to report on the project development

The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)

Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.

According to many observers we are standing on the precipice

It was encouraging to see so many partners at the 2017 General Assembly meeting last December

In the UK we have a saying that you wait hours for a bus and then two come along at once.

Last night saw a collection of the UK’s great and the good in clinical pharmacology

High functioning investigator sites are essential to the delivery

RASP-UK underwent its third progress review by the MRC on 19 May.

Because new biologic treatments for asthma can be expensive and cause side effects,

In this case the plan is a paradigm shift in the way we will manage

Welcome everyone to the first issue of the Frailomic consortium

The US Army has a new secret weapon – napping.

Advisory board meetings are often used to address perceived knowledge gaps and build consensus.

Our publication on effectiveness of a multimodal intervention

2012 has been a very busy year for the MID-Frail partners and the study consortium

Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians

Niche Science & Technology Ltd. are leading the team today awarded a Euro 7.5M

Frailty has a dramatic impact on the quality of life of many elderly people

Our group of academic and industry partners won a big MRC grant yesterday

Asthma is a chronic inflammatory disorder of the airways

Metathesiophobia: from Preclinical to Clinical Development

Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter

Welcome to the Frailomic Newsletter Update for 2016.

Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,

The EUropean Federation for Exploratory MEdicines Development (EUFEMED

Here are a few lists of the best of the best over the last 12 months.

We have just released our latest Frailomic consortium

The New Year started excellently for MID-Frail with the first patients

We all have a responsibility to encourage young people to study science

Having worked in early-stage clinical pharmacology for over 30 years

Deep Breath is the official newsletter of the UKs Refactory Asthma

Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.